ArticleJournal of clinical medicine2025
Efficacy and Safety of Switching from Adalimumab Originator to SB5 Biosimilar in Noninfectious Uveitis: Early Clinical Outcomes.
Ji Hun Song et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.